PD-L1 on either tumor cells or host immune cells is proposed to function in preventing T cell-mediated tumor killing. PD-1 is highly expressed in exhausted effector T cells. PD-L1 is constitutively expressed in some tumors and host immune cells, and its expression can be induced or maintaine...
At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP (p <...
Furthermore, PD-L1 seems to play not only a role in the interaction with PD-1 on lymphocytes, but also by itself on tumor cells by inducing cell proliferation, as it has been reported in literature that PD-L1 expression increases the levels of Ki-67 and other proteins involved in tumor ...
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarify predictive biomarkers for drug efficacy ...
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 2016; 6:... T Kato - 《International Journal of Urology》 被引量: 0发表: 2022年 Soluble PD-L1 changes in advanced non-small cell lung cancer pati...
逃避抗肿瘤免疫是肿瘤的一个标志,因而各类肿瘤免疫疗法被开发,如免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)和T细胞再定向双特异性抗体(T-cell–redirecting bispecifics,TCBS)等。虽然免疫治疗延长了各类肿瘤患者的生存时间,但全身免疫激活...
逃避抗肿瘤免疫是肿瘤的一个标志,因而各类肿瘤免疫疗法被开发,如免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)和T细胞再定向双特异性抗体(T-cell–redirecting bispecifics,TCBS)等。虽然免疫治疗延长…
Several targeted immunotherapies have recently showed significant advances in treatment of non-small cell lung cancer (NSCLC), including antibodies and inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1). Tumor tissue samples were prosp
Preclinical studies demonstrated that radiation up-regulates PD-L1 expression in tumor cells, providing a rationale for combining PD-1/PD-L1 inhibitors with radiation. However this has not been validated in patients with non-small cell lung cancer due to the difficulty to obtain serial biopsies. ...
Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes